KYSCO logo

Trial Details

A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease

NCT06088979

RECRUITING

DESCRIPTION


Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

CONDITIONS


Thyroid Eye Disease

ELIGIBILITY CRITERIA


Trial Location Information

University of Louisville Health Eye Institute Site - 0108

Louisville

Kentucky

40202


Loading...